Research
Hormonal
The dual agonist I-M-150847 facilitates rapid redistribution and recycling of GLP-1 receptors to the plasma membrane, maintaining them in a sensitized state, unlike monoagonists which cause prolonged internalization.
This mechanism explains why dual agonists might work better: they keep the insulin-stimulating receptors 'ready' on the cell surface rather than hiding them inside the cell for long periods. This is a molecular detail relevant to drug developers.
ModerateSupportsMEDIUM confidence
I-M-150847 induces rapid redistribution of GLP-1R at the plasma membrane following activation ensuring the maintenance of the receptor in a sensitized state.
Why this rating
Mechanistic data from in vitro cell culture and rodent models.
Source
I-M-150847, a novel GLP-1 and GIP receptor dual agonist, improves glycemic control and reduces obesity in the rodent model of type 2 diabetes and obesity
Rathin Bauri et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2021
DOI 10.1101/2021.12.05.471325
preprint · n=36
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →